Results 151 to 160 of about 31,524 (206)

Multiple inflammatory cytokines correlate with the vestibular and oculomotor dysfunction in Fabry disease: a prospective, longitudinal study. [PDF]

Front Immunol
Leng Y, Yuan Y, Zhao Y, Wang X, Ma J, Zhang X, Huang J, Hao H, Zhao G, Zhang W.   +9 more
europepmc   +1 more source

Boosting tribo-mechanical, thermal expansion and electrical performance of waste polytetrafluoroethylene using high-strength carbide ceramics. [PDF]

Sci Rep
Kamal A, Gaafer A, Mosleh AO, Taha MA.
europepmc   +1 more source

Correction: Correlation of retinal vascular characteristics with laboratory and ocular findings in Fabry disease: exploring ocular diagnostic biomarkers. [PDF]

Orphanet J Rare Dis
Lindziute M, Kaufeld J, Hufendiek K, Volkmann I, Brockmann D, Hosari S, Hohberger B, Mardin C, Framme C, Tode J, Hufendiek K.   +10 more
europepmc   +1 more source

Effects of Catfish Egg Lectin on Cancer Cells Differ According to the Globotriaosylceramide Species They Express. [PDF]

Int J Mol Sci
Sugawara S, Kikuchi K, Tatsuta T, Fujimura T, Hosono M.   +4 more
europepmc   +1 more source

Therapeutic landscape of Fabry disease: advances and challenges from classical strategies to emerging therapies. [PDF]

Front Med (Lausanne)
Zhang M, Wang C.
europepmc   +1 more source

Newborn Screening in Fabry Disease. [PDF]

Int J Mol Sci
Olszewska M, Schwermer K, Pawlaczyk K.
europepmc   +1 more source

Sphingolipid metabolic enzyme GLA expression in gliomas: prognostic implications and therapeutic potential. [PDF]

Front Oncol
Wei D, Su Q, Li X, Li H, Jin D, Pan Z, Yang M, Liu G, Du Y, Dong W.   +9 more
europepmc   +1 more source

Coexistence of Alport Syndrome and Fabry Disease in a Female with R112H Variant: Early Progression of Fabry Nephropathy. [PDF]

Int J Mol Sci
Grimaldi A, Auletta A, Ciurli F, Aiello V, Vischini G, Fabbrizio B, Becherucci F, Pasquinelli G, La Manna G, Capelli I, Mignani R.   +10 more
europepmc   +1 more source

Inflammation in Cardiomyopathies: Cellular Mechanisms Across Cardiac Phenotype. [PDF]

Cells
Lattanzio A, Marchionni G, Pecci G, Ciccarelli F, Stavagna S, Costantino J, Ballatore F, Alfarano M, Ciciarello F, Chimenti C.   +9 more
europepmc   +1 more source

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study. [PDF]

Orphanet J Rare Dis
Holida M, Linhart A, Longo N, Wallace E, Tøndel C, Hughes D, Warnock DG, Pisani A, Eyskens F, Deegan P, Feldt-Rasmussen U, Goker-Alpan O, Mehta A, Piotti G, Fichera V, Wang M, Chertkoff R, Waldek S, Wilcox WR, Bernat JA.   +19 more
europepmc   +1 more source